COPENHAGEN/LONDON (Reuters) - Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and ...

COPENHAGEN/LONDON >> Obesity drug maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company’s weight loss and diabetes drugs Wegovy and ...

Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.

Novo Nordisk, the Danish drug maker of the wildly successful obesity drugs, Wegovy and Ozempic, said it plans to invest $4.1 billion for a new plant in the United States to increase the ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Novo Nordisk A/S is set to invest $4.1 billion in expanding its U.S. manufacturing operations to meet the increasing demand for its weight loss drugs.

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its ...

Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on ...

COPENHAGEN/LONDON June 24 - Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes ...